Skip to Main content Skip to Navigation
Journal articles

Emerging drugs for hepatitis B.

Abstract : Chronic hepatitis B remains a treatment challenge despite the availability of new nucleoside analogs. This is due to the persistence of viral infection during therapy, which exposes the patient to the risk of developing antiviral drug resistance. Therefore, new polymerase inhibitors are needed to manage resistance to existing drugs and new trials of combination therapy are required to delay drug resistance. In the future, antiviral agents targeting other steps of the viral life cycle will be needed to achieve antiviral synergy and prevent antiviral drug resistance. Immune modulators are also expected to enhance antiviral response and to achieve sustained response. Discovery of new antiviral drugs and design of new treatment strategies are, therefore, needed to manage this disease, which is still the main cause of cirrhosis and hepatocellular carcinoma worldwide.
Complete list of metadatas

Cited literature [88 references]  Display  Hide  Download

https://www.hal.inserm.fr/inserm-00162225
Contributor : Fabien Zoulim <>
Submitted on : Tuesday, November 10, 2009 - 4:27:55 PM
Last modification on : Wednesday, November 20, 2019 - 3:18:12 AM
Long-term archiving on: : Thursday, April 8, 2010 - 11:07:03 PM

Identifiers

Collections

Citation

Fabien Zoulim. Emerging drugs for hepatitis B.. Expert Opinion on Emerging Drugs, Informa Healthcare, 2007, 12 (2), pp.199-217. ⟨10.1517/14728214.12.2.199⟩. ⟨inserm-00162225⟩

Share

Metrics

Record views

954

Files downloads

1359